←
Adaptive Biotech2,622 posts
Adaptive Biotech avatar

Adaptive Biotech

@AdaptiveBiotech

Adaptive Biotechnologies is a pioneer & leader in immune-driven medicine. We aim to improve lives by learning from the wisdom of our adaptive immune systems.

◷ Joined April 2012▧ 795 Photos and videos
Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·9h

Approximately 100 abstracts featuring clonoSEQ® MRD testing will be presented at #ASH26, highlighting its central role in advancing MRD assessment across hematology—from evaluating treatment response to informing treatment strategies and patient care. adaptivebio.tech/67a058

Post attachmentPost attachment
Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Oct 8

The science behind clonoSEQ® continues to build. With more than 300 peer-reviewed publications across ALL, CLL, DLBCL, MCL and multiple myeloma, clonoSEQ is one of the most extensively studied MRD tests in blood cancer.

Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Oct 5

Adaptive has achieved @My_Green_Lab Certification at the Gold level for our MRD R&D lab. We’re proud of the team who evaluated and updated practices to help reduce waste, conserve water, lower energy use, and implement training to support long-term environmental stewardship.

Post attachment
Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Sep 21

MRD data continue to define new standards of care in #multiplemyeloma. An expanded analysis from the Ph 3 CEPHEUS study is a powerful example of #MRD helping differentiate therapies and move clinical practice forward. Read the study in Blood Advances: adaptivebio.tech/pvf

Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Sep 17

Updated NCCN® Guidelines now include a dedicated MRD testing page, identify 10⁻⁶ as the preferred sensitivity and specifically name clonoSEQ® as an FDA-cleared assay for MRD assessment. Read more: adaptivebio.tech/98m

Post attachment
Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Jul 27

clonoSEQ® MRD testing adoption is rooted in strong clinical evidence—but it also needs to work seamlessly in real-world care.

1:05
Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Jul 8

As MRD adoption accelerates, clinical practice is evolving—especially in the community. 🎥 Jay Patel, Dir., Medical Affairs, on how clonoSEQ® is being leveraged in the community setting

0:54
Adaptive Biotech avatar
Adaptive Biotech@AdaptiveBiotech·Jun 18

As MRD moves into routine care, what matters most is having an approach that is deeply validated, highly sensitive and specific, and widely adopted across both clinical trials and real-world practice. 🎥 Hear more from Mary Pat Lancelotta, SVP MRD Biopharma

0:50